MSFP
EIGR

Mark Sheptoff Financial Planning’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1
Closed -$1K – 378
2016
Q1 		$1K Hold
1
– – ﹤0.01% 342
2015
Q4 		$1K Hold
1
– – ﹤0.01% 373
2015
Q3 		$1K Hold
1
– – ﹤0.01% 388
2015
Q2 		$1K Sell
1
-18
-95% -$49.8K ﹤0.01% 377
2015
Q1 		$163K Buy
+19
New +$166K 0.14% 103

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Mark Sheptoff Financial Planning's EIGR Position: Q2 2016 in Review

Mark Sheptoff Financial Planning sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2016, closing a stake of 1 share — an estimated $1K sold.

Mark Sheptoff Financial Planning first reported a position in EIGR in Q1 2015 and held it in 5 quarters. The position peaked at $163K in Q1 2015. 45 funds tracked by Wall St. Rank hold EIGR as of Q2 2016.

  • Mark Sheptoff Financial Planning reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Mark Sheptoff Financial Planning sold 1 Eiger BioPharmaceuticals, Inc. share in Q2 2016, an estimated $1K.
  • Mark Sheptoff Financial Planning first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 5 quarters.
  • Mark Sheptoff Financial Planning's Eiger BioPharmaceuticals, Inc. position peaked at $163K in Q1 2015.
  • 45 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2016.

Based on Mark Sheptoff Financial Planning's 13F filing for Q2 2016, filed 9 Aug 2016.